Special Issue

Host-Microbe Interactions in Clinically Relevant *Acinetobacter* spp.: New Models of *Acinetobacter* spp. Virulence and Its Interactions with Antibiotic Resistance

Message from the Guest Editor

The most important determinant in clinical outcome of *Acinetobacter* infections is antibiotic resistance. The role of resistance in affecting intrinsic virulence is complex. Several virulence models have been developed for the study of *Acinetobacter* infections. Almost all of these models are tested in the absence of antibiotics, so the results and conclusions obtained show the weakness of not reproducing the reality of the clinical picture of an infected patient, who is treated with antibiotics from the moment *Acinetobacter* spp. is identified as causative agent of infection. Therefore, a limitation of current models of virulence and infection are that they are not performed in the presence of antibiotics and do not account for antibiotic treatment when assessing an organism's virulence potential. This special issue requests that articles be sent in which all types of *Acinetobacter* spp infection models are tested in the presence of the first or second line antibiotics most used to treat these infections. **Keywords**: *Acinetobacter*; resistance; infection; virulence mode; antibiotic

Guest Editor

Dr. Jesús Navas

Grupo BIOMEDAGE, Facultad de Medicina, Universidad de Cantabria, Herrera Oria 2, 39011 Santander, Spain

Deadline for manuscript submissions

closed (15 June 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/57637

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI